From the medical board of the national psoriasis foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis

Journal of the American Academy of Dermatology

Volumn 70, Issue 1, 2014, Pages 178-186

  Motaparthi, Kiran ^a   Stanisic, Vladimir ^a   Van Voorhees, Abby S ^b   Lebwohl, Mark G ^c   Hsu, Sylvia ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

anti tumor necrosis factor alfa; biologic therapy; cyclosporine; hepatitis B; methotrexate; psoriasis; ustekinumab

Indexed keywords

CYCLOSPORIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; METHOTREXATE; USTEKINUMAB;

ACUTE HEPATITIS; CHRONIC HEPATITIS; COMORBIDITY; FOLLOW UP; HEPATITIS B; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION TEST; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; REVIEW; SCREENING TEST; SERODIAGNOSIS;

EID: 84890799601     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.08.049     Document Type: Article

References (51)

1. S. Hsu, K.A. Papp, M.G. Lebwohl, J. Bagel, A. Blauvelt, and K.C. Duffin Consensus guidelines for the management of plaque psoriasis Arch Dermatol 148 2012 95 102
2. G. Herbein, and W.A. O'Brien Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis Proc Soc Exp Biol Med 223 2000 241 257
3. C.M. Mastroianni, M. Lichtner, R. Citton, C. Del Borgo, A. Rago, and H. Martini Current trends in management of hepatitis B virus reactivation in the biologic therapy era World J Gastroenterol 17 2011 3881 3887
4. Centers for Disease Control and Prevention. Hepatitis B information for health professionals. Available from: URL: http://www.cdc.gov/hepatitis/hbv/ hbvfaq.htm. Accessed August 6, 2012.
5. C.M. Weinbaum, I. Williams, E.E. Mast, S.A. Wang, L. Finelli, and A. Wasley Recommendations for identification and public health management of persons with chronic hepatitis B virus infection MMWR Recomm Rep 57 2008 1 20
6. M. Morgan, and E.B. Keeffe Diagnosis and treatment of chronic hepatitis B: 2009 update Minerva Gastroenterol Dietol 55 2009 5 22
7. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
8. R. de Franchis, A. Hadengue, G. Lau, D. Lavanchy, A. Lok, and N. McIntyre European Association for Study of the Liver (EASL) international consensus conference on hepatitis B: 13-14 September, 2002 Geneva, Switzerland; consensus statement (long version) J Hepatol 45 2003 S3 S25
9. A.S. Lok, and B.J. McMahon Chronic hepatitis B Hepatology 45 2007 507 539
10. A. Post, and S. Nagendra Reactivation of hepatitis B: pathogenesis and clinical implications Curr Infect Dis Rep 11 2009 113 119
11. L.H. Calabrese, N.N. Zein, and D. Vassilopoulos Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Ann Rheum Dis 65 2006 983 989
12. J.H. Hoofnagle Reactivation of hepatitis B Hepatology 49 2009 S156 S165
13. M. Kato, T. Atsumi, T. Kurita, T. Odani, Y. Fujieda, and K. Otomo Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases J Rheumatol 38 2011 2209 2214
14. Y.J. Kim, S.C. Bae, Y.K. Sung, T.H. Kim, J.B. Jun, and D.H. Yoo Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases J Rheumatol 37 2010 346 350
15. R.A. Ponde, D.D. Cardoso, and M.O. Ferro The underlying mechanisms for the 'anti-HBc alone' serological profile Arch Virol 155 2010 149 158
16. Z.N. Said An overview of occult hepatitis B virus infection World J Gastroenterol 17 2011 1927 1938
17. W. Yeo, and P.J. Johnson Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy Hepatology 43 2006 209 220
18. Y.T. Cho, C.H. Chen, H.Y. Chiu, and T.F. Tsai Use of anti-tumor necrosis factor-alpha therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan J Dermatol 39 2012 269 273
19. J.S. Lubel, and P.W. Angus Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management J Gastroenterol Hepatol 25 2010 864 871
20. W. Yeo, P.K. Chan, S. Zhong, W.M. Ho, J.L. Steinberg, and J.S. Tam Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors J Med Virol 62 2000 299 307
21. A.S. Lok, and C.L. Lai Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection: incidence, predisposing factors and etiology J Hepatol 10 1990 29 34
22. A.S. Lok, R.H. Liang, E.K. Chiu, K.L. Wong, T.K. Chan, and D. Todd Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study Gastroenterology 100 1991 182 188
23. R. Perez-Alvarez, C. Diaz-Lagares, F. Garcia-Hernandez, L. Lopez-Roses, P. Brito-Zeron, and M. Perez-de-Lis Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases Medicine (Baltimore) 90 2011 359 371
24. C.M. Chu, and Y.F. Liaw Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B Gastroenterology 133 2007 1458 1465
25. R.P. Perrillo Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease Gastroenterology 120 2001 1009 1022
26. M.B. Carroll, and M.I. Bond Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection Semin Arthritis Rheum 38 2008 208 217
27. C. Fotiadou, E. Lazaridou, and D. Ioannides Safety of anti-tumor necrosis factor-alpha agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature J Eur Acad Dermatol Venereol 25 2011 471 474
28. L. Nosotti, F. Francesconi, S. Izzi, E. Berardesca, A. Morrone, and C. Bonifati Safety of antitumor necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection Br J Dermatol 162 2010 1408 1410
29. N. Cassano, V. Mastrandrea, M. Principi, F. Loconsole, N. De Tullio, and A. Di Leo Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease J Biol Regul Homeost Agents 25 2011 285 289
30. F. Prignano, F. Ricceri, L. Pescitelli, F. Zanieri, and T. Lotti Tumor necrosis factor-alpha antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients Br J Dermatol 164 2011 645 647
31. A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850
32. M. Lebwohl, J. Bagel, J.M. Gelfand, D. Gladman, K.B. Gordon, and S. Hsu From the medical board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis J Am Acad Dermatol 58 2008 94 105
33. J.G. Stine, M. Bass, D. Ibrahim, O.S. Khokhar, and J.H. Lewis Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-alpha inhibitor therapy South Med J 104 2011 781 788
34. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
35. G. Raftery, B. Griffiths, L. Kay, and D. Kane Chronic viral hepatitis and TNF-alpha blockade Rheumatology (Oxford) 46 2007 1381
36. J.F. Rahier, M. Moutschen, A. Van Gompel, M. Van Ranst, E. Louis, and S. Segaert Vaccinations in patients with immune-mediated inflammatory diseases Rheumatology (Oxford) 49 2010 1815 1827
37. K.G. Saag, G.G. Teng, N.M. Patkar, J. Anuntiyo, C. Finney, and J.R. Curtis American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 2008 762 784
38. R. Navarro, E. Vilarrasa, P. Herranz, L. Puig, X. Bordas, and J.M. Carrascosa Safety and effectiveness of ustekinumab and anti-tumor necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicenter study in a clinical setting Br J Dermatol 168 2013 609 616
39. W.L. Xia, H.Y. Xie, Y. Shen, L.M. Wu, F. Zhang, and S.S. Zheng Effects of cyclosporin and tacrolimus on replication of hepatitis B virus in vitro: a comparative study Zhonghua Yi Xue Za Zhi 86 2006 111 115
40. X. Tian, C. Zhao, H. Zhu, W. She, J. Zhang, and J. Liu Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection J Virol 84 2010 3373 3381
41. W.L. Xia, Y. Shen, and S.S. Zheng Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms Hepatobiliary Pancreat Dis Int 4 2005 18 22
42. H.Y. Xie, W.L. Xia, C.C. Zhang, L.M. Wu, H.F. Ji, and Y. Cheng Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment Acta Pharmacol Sin 28 2007 975 984
43. X.B. Pan, J.C. Han, Y. Gao, and L. Wei Cyclosporine A improves the nuclear entry of hepatitis B virus core protein in HepG2.2.15 cells Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 21 2007 310 312
44. X.Y. Liu, L.X. Yu, S.J. Fu, J. Xu, C.F. Du, and W.F. Deng Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients Nan Fang Yi Ke Da Xue Xue Bao 27 2007 1090 1092
45. T. Yagisawa, H. Toma, K. Tanabe, N. Ishikawa, N. Tokumoto, and Y. Iguchi Long-term outcome of renal transplantation in hepatitis B surface antigen-positive patients in cyclosporin era Am J Nephrol 17 1997 440 444
46. J.C. Cobeta García, and M. Medrano Reactivation of hepatitis B in a patient with spondyloarthritis after the suspension of methotrexate and efficacy of treatment with antivirals in association to adalimumab Rheumatol Clin 7 2011 200 202
47. H. Hagiyama, T. Kubota, Y. Komano, M. Kurosaki, M. Watanabe, and N. Miyasaka Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis Clin Exp Rheumatol 22 2004 375 376
48. S. Ito, K. Nakazono, A. Murasawa, Y. Mita, K. Hata, and N. Saito Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient Arthritis Rheum 44 2001 339 342
49. G.Y. Gwak, K.C. Koh, and H.Y. Kim Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate Clin Exp Rheumatol 25 2007 888 889
50. P. Ostuni, C. Botsios, L. Punzi, P. Sfriso, and S. Todesco Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate Ann Rheum Dis 62 2003 686 687
51. K. Watanabe, K. Takase, S. Ohno, H. Ideguchi, A. Nozaki, and Y. Ishigatsubo Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate Mod Rheumatol 22 2012 470 473